• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Still a place for hormone replacement therapy?].

作者信息

Gompel Anne

机构信息

Université Paris-Descartes, Port Royal-Cochin, unité de gynécologie médicale, 75014 Paris, France.

出版信息

Presse Med. 2013 Nov;42(11):1521-5. doi: 10.1016/j.lpm.2013.04.019. Epub 2013 Nov 8.

DOI:10.1016/j.lpm.2013.04.019
PMID:24210642
Abstract

Hormone replacement therapy (HRT) remains the most efficient treatment to alleviate climacteric symptoms. The drastic decline in their prescription following the WHI is not fully justified. Benefits might be more important than harm in women 50-60 years. French way of treatment does not increase the risk in thrombosis nor stroke and breast cancer risk is less important than with other regimen. One of the major benefits of HRT is the decrease in type 2 diabetes with all the treatments including the French ones. The results of the American randomized trials cannot be fully extrapolated to young postmenopausal women with less cardiovascular risk factors.

摘要

相似文献

1
[Still a place for hormone replacement therapy?].
Presse Med. 2013 Nov;42(11):1521-5. doi: 10.1016/j.lpm.2013.04.019. Epub 2013 Nov 8.
2
Lessons learned from the WHI: HRT requires a cautious and individualized approach.从妇女健康倡议(WHI)中吸取的教训:激素替代疗法(HRT)需要谨慎且个体化的方法。
Geriatrics. 2004 Nov;59(11):22-6.
3
[Clinical study of the month. Benefit/risk balance of postmenopausal estrogen-progestin treatment in peril in the Women's Health Initiative study: practical attitude of the clinician].[本月临床研究。女性健康倡议研究中绝经后雌激素 - 孕激素治疗的风险/获益平衡:临床医生的实际态度]
Rev Med Liege. 2002 Aug;57(8):556-62.
4
Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.更年期医学:欧洲更年期与男性更年期协会(EMAS)2004/2005年关于围绝经期和绝经后激素替代疗法的立场声明。
Maturitas. 2005 May 16;51(1):8-14. doi: 10.1016/j.maturitas.2005.02.019.
5
The 'timing hypothesis' for estrogen therapy in menopausal symptom management.用于更年期症状管理的雌激素疗法的“时机假说”
Womens Health (Lond). 2015 Jul;11(4):437-40. doi: 10.2217/WHE.15.24. Epub 2015 Aug 3.
6
Recent epidemiological evidence relevant to the clinical management of the menopause.与更年期临床管理相关的最新流行病学证据。
Climacteric. 2007 Oct;10 Suppl 2:2-15. doi: 10.1080/13697130701606754.
7
A personal initiative for women's health: to challenge the Women's Health Initiative.一项针对女性健康的个人倡议:挑战女性健康倡议组织。
Gynecol Endocrinol. 2002 Aug;16(4):255-7.
8
Reassurance for many healthy women considering HRT.这让许多考虑激素替代疗法(HRT)的健康女性放心了。
BMJ. 2017 Oct 13;359:j4652. doi: 10.1136/bmj.j4652.
9
Health risks after cessation of postmenopausal hormone therapy.绝经后激素治疗停止后的健康风险。
Climacteric. 2008 Jun;11(3):179-80. doi: 10.1080/13697130802176228.
10
Evidence-based assessment of the impact of the WHI on women's health.基于证据的 WHI 对女性健康影响的评估。
Climacteric. 2012 Jun;15(3):281-7. doi: 10.3109/13697137.2012.655564.